| VRTX | Vertex Pharmaceuticals Inc | 5.18% |
| BIIB | Biogen Inc | 5.08% |
| AMGN | Amgen Inc | 4.90% |
| RPRX | Royalty Pharma PLC Class A | 4.73% |
| ALNY | Alnylam Pharmaceuticals Inc | 4.63% |
| REGN | Regeneron Pharmaceuticals Inc | 4.46% |
| GILD | Gilead Sciences Inc | 4.29% |
| UTHR | United Therapeutics Corp | 4.25% |
| TECH | Bio-Techne Corp | 3.65% |
| VCYT | Veracyte Inc | 3.29% |
The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Index is comprised of securities of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.
Invesco Biotechnology & Genome ETF · Issued by Invesco
No recent news for PBE. The ingest cron pulls every 15 minutes during market hours.